drugset / Trial / NCT04683237

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

NCT04683237

RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

Timeline

Start
2021-03-20
Primary completion
2025-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg
Subject Megestrol Acetate Other / unclassified 160 mg Oral